Allergy Therapeutics PLC Stock
€0.084
Your prediction
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Allergy Therapeutics PLC | - | -8.197% | -2.326% | 76.842% | 22.628% | -58.824% | -55.789% |
Beximco Pharmaceuticals Ltd. GDR | -5.560% | -12.069% | 19.718% | 58.385% | 22.596% | -38.554% | -36.250% |
SELLAS Life Sciences Group Inc | -0.370% | 0.738% | 11.580% | 37.416% | 74.070% | -48.344% | -7.874% |
Eledon Pharmaceuticals Inc. | -1.820% | 0.000% | -20.588% | -13.600% | -47.059% | -40.659% | -61.039% |
News

Why EchoStar Is Skyrocketing Today
Shares of EchoStar (NASDAQ: SATS) jumped on Wednesday, closing the day up 15.5%. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both ticked up

AT&T Just Made a Smart $23 Billion Bet
Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of

Stock Market Today: Rally Holds as Tech and Industrials Lead Gains, Fed Changes Loom
U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%